Does starting allopurinol prolong acute treated gout? a randomized clinical trial

Journal of Clinical Rheumatology

Volumn 21, Issue 3, 2015, Pages 120-125

  Hill, Erica M ^a   Sky, Karen ^b   Sit, Michelle ^c   Collamer, Angelique ^d   Higgs, Jay ^a  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b Alaska Va Healthcare System and Regional Office   (United States)

^c DAVID GRANT MEDICAL CENTER   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

allopurinol; crystal; Gout

Indexed keywords

ALLOPURINOL; COLCHICINE; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; URIC ACID; ANTIGOUT AGENT;

ADULT; AGED; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION; URIC ACID BLOOD LEVEL; VOMITING; ACUTE DISEASE; BLOOD; COHORT ANALYSIS; DISEASE COURSE; DOSE RESPONSE; MIDDLE AGED; TIME; TREATMENT OUTCOME; VERY ELDERLY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; COHORT STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; URIC ACID;

EID: 84926665225     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000235     Document Type: Article

References (13)

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63:3136-3141.
2. Kuo CF, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study [published online ahead of print January 15, 2014]. Ann Rheum Dis.
3. Wu EQ, Patel PA, Yu AP, et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm. 2008;14: 164-175.
4. Li C, Martin BC, Cummins DF, et al. Ambulatory resource utilization and cost for gout in United States. Am J Pharm Benefits. 2013;5:e46-54.
5. Schumacher H, Chen L. Newer therapeutic approaches: gout. Rheum Dis Clin North Am. 2006;32:235-244.
6. Croft JD. Case 5: treatment options for acute gout. Am J Med. 2006;119 (11 suppl 1):S14-15.
7. Burns CM, Wortman RL. Chapter 95. Clinical features and treatment of gout. In: Firestein GS, Budd RC, Gabriel SE, et al, eds. Firestein: Kelley's Textbook of Rheumatology. 9th ed. Philadelphia, PA: Elsevier Saunders; 2013:1554-1575.
8. Schumacher HR, Chen LX. Chapter 333. Gout and other crystal-associated arthropathies. In: Kasper DLLongo DL, Fauci AS, et al, eds. Harrison's Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill; 2012.
9. Khanna D, FitzGerald JD, Khanna PP, et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) . 2012;64:1431-1446.
10. Schulz K, Altman D, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152:726-732.
11. Moher D, Hopewell S, Schulz K, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomized trials. BMJ. 2010;340:c869.
12. Buchbinder R, Bombardier C, Yeung M, et al. Which outcome measures should be used in rheumatoid arthritis clinical trials?: Clinical and quality-of-life measures' responsiveness to treatment in a randomized controlled trial. Arthritis Rheum. 1995;38:1568-1580.
13. Taylor TH, Mecchella JN, Larson RJ, et al. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med. 2012;125:1126-1134.